Immunotherapy is the latest word in cancer treatment. While medicine has progressed in applying immunotherapy to blood-related cancers, the application to solid tumors has been farther off in the distance.

Spearheading solutions on a global scale

The Cancer Immunotherapy Research Center is making progress on all fronts of cancer, with tremendous momentum toward decoding this enigma. Tel Aviv Sourasky Medical Center is privileged to have on its team a cancer immunotherapy pioneer, Prof. Zelig Eshhar, who directs the Basic Immunotherapy Research Lab and the bench-to-bedside clinical program. The cutting-edge pharmaceutical company, Kite Pharma, the only organization outside the U.S. that is leveraging Prof. Eshhar’s innovative technology, has developed a solution that the Medical Center has already used to treat its first patient successfully.

The compelling master plan based on award-winning science

Working to supercharge the immune system, the center genetically engineers and grows cancer-killing cells to recognize and go after cancer cells, suppresses the cells that prevent the immune system from destroying cancer cells and boosts the cells that teach the immune system to fight off cancer. The teams are studying biomarkers – biological measurements used to predict disease risk to help with prevention, early detection and monitoring treatment effectiveness. The center is also developing solutions to keep the body from rejecting donated stem cells after transplantation.

The dynamic setting where the seemingly impossible can happen

With its pre-clinical and clinical research plan, world-renowned team, novel methods and tissue bank for translational research, the Medical Center is uniquely positioned to pursue immunotherapy solutions. To proceed with this ambitious plan, the research center needs cleanroom lab facilities and a synergistic environment to foster progress, knowledge-sharing and scientific collaboration. Working together in the lab and with Hemato-Oncology Center and Oncology Center colleagues from throughout the world, the research center’s objective is to be the vanguard in cancer immunotherapy and, someday soon, be able to say: “We can cure cancer.”